Biomarin Pharmaceutical Stock News

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each shar...

BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.

BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.

BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.

BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.

BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.